Seacera Group barred from filing in court after stay bid dismissal, Enclosure 1 hearing set for Dec. 9
Bitget2026/10/08 09:17Seacera Group’s winding-up-related court matter moved closer to a key hearing, with Enclosure 1 still set for Dec. 9, 2026. A stay application in PW279 was dismissed on Oct. 1, 2026, limiting the company’s ability to take part in Enclosure 1. The court directed that Seacera Group cannot file documents or participate in the Enclosure 1 hearing. The liquidator will file an additional report by Nov. 6, 2026, with responses requiring court permission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seacera Group Bhd published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3713143) on October 08, 2026, and is solely responsible for the information contained therein.
- Seacera Group’s winding-up-related court matter moved closer to a key hearing, with Enclosure 1 still set for Dec. 9, 2026.
- A stay application in PW279 was dismissed on Oct. 1, 2026, limiting the company’s ability to take part in Enclosure 1.
- The court directed that Seacera Group cannot file documents or participate in the Enclosure 1 hearing.
- The liquidator will file an additional report by Nov. 6, 2026, with responses requiring court permission.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
